Revolutionizing Healthcare: Eko Health Raises $41 Million in Funding for Heart and Lung Disease Detection Technology

Eko Health, Inc., a pioneer in digital health technology, has successfully raised an impressive $41 million in its latest funding round. This significant investment underscores the growing confidence in Eko’s innovative approach to transforming the early detection and management of heart and lung diseases through advanced digital stethoscopes and its groundbreaking AI detection platform, SENSORA™. With FDA-cleared devices already in use by hundreds of thousands of healthcare professionals around the globe, Eko is at the forefront of a critical shift in how medical practitioners diagnose and treat respiratory and cardiac conditions. The newly acquired funds are earmarked for expanding Eko’s research and development efforts, driving innovations in AI capabilities, and enhancing their product lineup to meet the evolving needs of the healthcare community. Additionally, Eko plans to bolster its marketing initiatives to increase awareness and adoption of its technologies, which have proven to enable earlier detection, more accurate diagnoses, and improved patient outcomes. Headquartered in Emeryville, California, Eko Health continues to attract attention and support from prominent investors, including Highland Capital Partners, Questa Capital, and the Mayo Clinic. With over $125 million raised to date, Eko is strategically positioned to lead the charge in redefining patient care in the digital age, allowing healthcare professionals to deliver the best care possible to their patients. This funding round is not only a testament to Eko's current success but also a beacon of hope for the future of heart and lung health management.